HOLON, Israel, June 12,
2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN)
(TASE: CGEN) a clinical-stage cancer immunotherapy company and a
pioneer in computational target discovery, today announced the
presentation of AI/ML driven predictive computational research at
upcoming international scientific conferences reflecting Compugen's
scientific capabilities in understanding complex cancer
biology.
Poster details:
Conference: 2025 Annual Congress of the European
Association for Cancer Research, June
16-19 Lisbon, Portugal
Poster number: EACR25-3113
Title: Prediction of immune evasion and immunotherapy
resistance mechanisms associated with distinct TNBC subtypes
Presenting author: Amir Toporik, Computational Discovery,
Compugen
Date of presentation: June 18,
2025
Conference: International Society for Computational
Biology and European Conference on Computational Biology- Annual
International Conference on Intelligent Systems for Molecular
Biology, July 20-24, 2025,
Liverpool, UK
Poster number: 947
Title: Computational prediction of TNBC tumor subtypes from
an integrative single cell atlas elucidates immune evasion and
immunotherapy resistance mechanisms
Presenting author: Itamar
Borukhov, Ph.D., Computational Discovery, Compugen
Posters will be available in the publications section of
Compugen's website, www.cgen.com, following presentation.
About Compugen
Compugen is a
clinical-stage therapeutic discovery and development company
utilizing its broadly applicable predictive computational discovery
platform (UnigenTM) to identify new drug targets and
biological pathways for developing cancer immunotherapies. Compugen
has two proprietary product candidates in Phase 1 development:
COM701, a potential first-in-class anti-PVRIG antibody and
COM902, a potential best-in-class antibody targeting TIGIT for
the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT
bispecific antibody where the TIGIT component is derived from
Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase
3 development by AstraZeneca through a license agreement for the
development of bispecific and multispecific
antibodies. GS-0321 (previously COM503), a potential
first-in-class, high affinity anti-IL-18 binding protein antibody,
which is in Phase 1 development is licensed to Gilead. In addition,
the Company's therapeutic pipeline of
early-stage immuno-oncology programs consists of research
programs aiming to address various mechanisms to enhance
anti-cancer immunity. Compugen is headquartered in
Israel, with offices in
San Francisco, CA. Compugen's
shares are listed on Nasdaq and the Tel Aviv Stock Exchange
under the ticker symbol CGEN.
Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-to-present-aiml-driven-predictive-computational-research-at-upcoming-international-scientific-conferences-302480072.html
SOURCE Compugen Ltd.
